{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=62",
    "query": {
      "intervention": "Placebo- C",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 1835,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T19:36:25.754Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01289782",
      "title": "An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TMC435",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alpha-2a (PegIFN alpha-2a)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen R&D Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 395,
      "start_date": "2011-02",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 22,
      "location_summary": "Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01289782"
    },
    {
      "nct_id": "NCT02767089",
      "title": "The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adults"
      ],
      "interventions": [
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2005-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-10",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02767089"
    },
    {
      "nct_id": "NCT01763918",
      "title": "Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 331,
      "start_date": "2013-02-07",
      "completion_date": "2013-12-19",
      "has_results": true,
      "last_update_posted_date": "2019-06-17",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763918"
    },
    {
      "nct_id": "NCT05061797",
      "title": "A Study to Examine the Effect of a Thermogenic Energy Drink in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolism"
      ],
      "interventions": [
        {
          "name": "Thermogenic Energy Drink - Active Study Product Formula",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Rowdy Energy",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-08-23",
      "completion_date": "2021-11-16",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 1,
      "location_summary": "Addison, Illinois",
      "locations": [
        {
          "city": "Addison",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05061797"
    },
    {
      "nct_id": "NCT06106646",
      "title": "Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma",
        "Pulmonary Function",
        "Wheezing",
        "In Utero Nicotine"
      ],
      "interventions": [
        {
          "name": "No active intervention in this protocol (previously randomized to Vitamin C)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "No active intervention in this protocol (previously randomized to Placebo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 225,
      "start_date": "2023-10-11",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Portland, Oregon",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06106646"
    },
    {
      "nct_id": "NCT00214461",
      "title": "Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clostridium Infections"
      ],
      "interventions": [
        {
          "name": "Vaccine diluent buffer (Placebo)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "C. difficile toxoid vaccine (2 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "C. difficile toxoid vaccine (10 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "C. difficile toxoid vaccine (50 µg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2005-11",
      "completion_date": "2006-02",
      "has_results": true,
      "last_update_posted_date": "2012-04-11",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Lexington, Kentucky",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00214461"
    },
    {
      "nct_id": "NCT03997786",
      "title": "A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Moderate-to-severe Chronic Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Tildrakizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "215 Months",
        "sex": "ALL",
        "summary": "6 Years to 215 Months"
      },
      "enrollment_count": 135,
      "start_date": "2020-01-15",
      "completion_date": "2031-08-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 5,
      "location_summary": "Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03997786"
    },
    {
      "nct_id": "NCT01351805",
      "title": "Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autoimmune Diseases",
        "Systemic Inflammatory Process",
        "Knee Pain Chronic",
        "Osteoarthritis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Fish Oil",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo pill",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 25871,
      "start_date": "2010-07",
      "completion_date": "2025-02",
      "has_results": true,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01351805"
    },
    {
      "nct_id": "NCT02549170",
      "title": "A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
      ],
      "interventions": [
        {
          "name": "HYQVIA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.25% albumin placebo solution with rHuPH20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGIV GAMMAGARD LIQUID/KIOVIG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGIV GAMUNEX®-C",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2015-12-15",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02549170"
    },
    {
      "nct_id": "NCT01582269",
      "title": "A Study in Recurrent Glioblastoma (GB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Galunisertib",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2012-04-26",
      "completion_date": "2024-10-10",
      "has_results": true,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-11-03T19:36:25.754Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582269"
    }
  ]
}